The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
Abstract
An intracellular delivery system for CRISPR/Cas9 is crucial for its application as a therapeutic genome editing technology in a broad range of diseases. Current vehicles carrying CRISPR/Cas9 limit in vivo delivery because of low tolerance and immunogenicity; thus, the in vivo delivery of genome editing remains challenging. Here, we report that cancer-derived exosomes function as natural carriers that can efficiently deliver CRISPR/Cas9 plasmids to cancer. Compared to epithelial cell-derived exosomes, cancer-derived exosomes provide potential vehicles for effective in vivo delivery via selective accumulation in ovarian cancer tumors of SKOV3 xenograft mice, most likely because of their cell tropism. CRISPR/Cas9-loaded exosomes can suppress expression of poly (ADP-ribose) polymerase-1 (PARP-1), resulting in the induction of apoptosis in ovarian cancer. Furthermore, the inhibition of PARP-1 by CRISPR/Cas9-mediated genome editing enhances the chemosensitivity to cisplatin, showing synergistic cytotoxicity. Based on these results, tumor-derived exosomes may be very promising for cancer therapeutics in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another case, CRISPR/Cas9 technology has been loaded into synthetic exosomes to specifically target cancerous cells for gene editing, offering a potential new approach to treating genetic disorders and certain types of cancers [45].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [45]
In the citing paper
“The CRISPR/Cas9-loaded exosomes significantly down-regulated PARP-1 expression, thus causing ovarian cancer cell death [54].”
From The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System (2022) · cites this paper as [54]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature reviews. Immunology · doi:10.1038/nri855 · Cited by 5,355
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,672
Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function
Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., & Mi, S. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.02.001 · Cited by 1,901
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 480
Abouali, H., Hosseini, S. A., Purcell, E., Nagrath, S., & Poudineh, M. (2022) · Cancers · doi:10.3390/cancers14020288 · Cited by 16
“EVs have also been recently used to deliver novel therapeutics, including siRNA and CRISPR/Cas-9, to specifically induce cell death in vivo and in vitro, respectively [72,73].”
MethodBanerjee, A., Lino, M. M., Jesus, C., Ribeiro, Q., Abrunhosa, A., & Ferreira, L. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.039 · Cited by 18
Kakiuchi, Y., Kuroda, S., Kanaya, N., Kagawa, S., Tazawa, H., & Fujiwara, T. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2259102 · Cited by 16
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges
Liu, T., Sun, L., Ji, Y., & Zhu, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189101 · Cited by 17
Mohak, S., & Fábián, Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050641 · Cited by 18
“Indeed, EVs carrying CRISPR/Cas9-encoding plasmids targeting the poly (ADP-ribose) polymerase-1 ( PARP-1 ) gene were shown to block PARP-1 in ovarian cancer cells, demonstrating preserved transcriptional activity of the recombinant DNA cargo during delivery [150].”
Baig, M. M. F. A., Chien, W. T., & Chair, S. Y. (2025) · Biomaterials Science · doi:10.1039/d5bm00711a · Cited by 19
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance
Zhang, P., Chen, K., Liu, W., Niu, X., Wang, X., Wang, J., Yao, W., Tang, X., & Tian, W. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1608480 · Cited by 17
Vascular transplantation with dual-biofunctional ePTFE vascular grafts in a porcine model
Zheng, X., Wu, S., Zhao, C. F., Bai, Y., Jin, D., Yin, M., Liu, H., & Fan, Y. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01398j · Cited by 16
Exosomes-mediated tumor treatment: One body plays multiple roles
Xu, N., Guo, R., Yang, X., Li, N., Yu, J., & Zhang, P. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.08.003 · Cited by 16
CRISPR /Cas gene editing and delivery systems for cancer therapy
Li, Y., Zhou, S., Wu, Q., & Gong, C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1938 · Cited by 16
Jiang, M., Zhang, K., Meng, J., Xu, L., Liu, Y., & Wei, R. (2024) · International Journal of Cancer · doi:10.1002/ijc.35241 · Cited by 16
“153 In another study, the exosomal CD9 was fused with an RNA-binding protein to enhance the enrichment of CRISPR/Cas9 into exosomes.”
Noormohamadi, H., Samarkhazan, H. S., Kargar, M., Maroufi, F., Servatian, N., & Davami, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03383-5 · Cited by 17
“In order to mitigate the risks associated with prolonged expression of bacterial Cas9, this platform was designed to encapsulate CRISPR/ Cas9 payload as plasmid DNA or in a more transient format, specifically mRNA and RNP [116].”
Cornet-Gómez, A., Moreira, L. R., Kronenberger, T., & Osuna, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-34820-6 · Cited by 15
Mousavi, S. M., Hashemi, S. A., Kalashgrani, M. Y., Rahmanian, V., Riazi, M., Omidifar, N., Althomali, R. H., Rahman, M. M., Chiang, W., & Gholami, A. (2023) · ChemMedChem · doi:10.1002/cmdc.202300359 · Cited by 15
Extracellular vesicle-mediated communication between CD8+ cytotoxic T cells and tumor cells
Huang, Z., Liu, X., Guo, Q., Zhou, Y., Shi, L., Cai, Q., Tang, S., Ouyang, Q., & Zheng, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1376962 · Cited by 15
He, C., Ali, D. J., Li, Y., Zhu, Y., Sun, B., & Xiao, Z. (2020) · PeerJ · doi:10.7717/peerj.9524 · Cited by 15
“exosomes have been shown to have unique advantages for delivery vehicles as they can exert cell specific tropism (Kim et al., 2017).”
BackgroundMethodInfluentialMehnath, S. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf127 · Cited by 14
Mu, S., Qian, T., Li, Z., Zhao, P., Tao, Y., Chang, H., & Qu, F. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155595 · Cited by 14
In vivoimaging and tracking of exosomes for theranostics
Ma, N., Wu, C., & Meng, Z. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545821300056 · Cited by 15
The Role of Exosomes in the Female Reproductive System and Breast Cancers
Bai, Y., Guo, J., Liu, Z., Li, Y., Jin, S., & Wang, T. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s281909 · Cited by 14
Ali, D. J., He, C., Xu, H., Kumaravel, S., Sun, B., Zhou, Y., Liu, R., & Xiao, Z. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119149 · Cited by 14
Xu, H., Liu, R., Zhou, H., Kong, B., Shen, K., Zhao, T., Du, X., Zhang, H., Song, H., Guo, D., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.029 · Cited by 15
“On the other hand, Kim et al. loaded SKOV3-derived sEVs with CRISPR plasmids by electroporation; the vesicles ablated the poly (ADP-ribose) polymerase-1 ( PARP1) locus in ovarian-cancer xenografts and suppressed tumor growth due to cancer tropism-dependent targeting of tumor-derived sEVs [137].”
Ge, X., Shan, S., Lu, H., Wang, W., Gao, C., & Fu, S. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s572435 · Cited by 15
Lin, J., Jia, S., Jiao, Z., Chen, J., Li, W., Cao, F., & Zhang, X. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00507-z · Cited by 13
“Although EVs have potential for delivering CRPSIR/ Cas products, owing to source issues, many EV biomacromolecules have the potential to affect cellular physiological functions, such as tumor-derived EVs, which may lead to tumor development and metastasis [66].”
BackgroundNext-generation biological vector platforms for in vivo delivery of genome editing agents
Leclerc, D., Siroky, M. D., & Miller, S. M. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103040 · Cited by 16
Organogels: “GelVolution” in Topical Drug Delivery - Present and Beyond
Nikam, A. N., Roy, A., Raychaudhuri, R., Navti, P. D., Soman, S., Kulkarni, S., Shirur, K. S., Pandey, A. P., & Mutalik, S. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128279479231231092905 · Cited by 13
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Gomari, M. M., Ghantabpour, T., Pourgholam, N., Rostami, N., Hatfield, S. M., Namazifar, F., Abkhiz, S., Eslami, S. S., Ramezanpour, M., Darestanifarahani, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70002 · Cited by 17
“Additionally, Kim et al. utilized exosomes derived from OV to deliver CRISPR/Cas9 plasmids targeting poly(ADP-ribose) polymerase-1, resulting in a significant reduction in tumor volume in vivo [356].”
Raza, M. A., Khatoon, N., Parveen, R., Nirisha, V., Thakur, Y., Thakur, Y., Lata, K. A., Shifana, A. S., Disouza, J., Saoji, S. D., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145145 · Cited by 14
Exosomes and MicroRNAs in Biomedical Science
Mirzaei, H., Rahimian, N., Mirzaei, H. R., Nahand, J. S., & Hamblin, M. R. (2022) · Synthesis lectures on biomedical engineering · doi:10.2200/s01171ed1v01y202202bme062 · Cited by 27
Cheng, Z., Shang, J., Wang, H., Yu, L., Zhu, Y., Zhang, Y., Du, Y., & Tian, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.040 · Cited by 12
Mitchell, M. D., Crookenden, M. A., Vaswani, K., Roche, J. R., & Peiris, H. N. (2018) · Animal Production Science · doi:10.1071/an18579 · Cited by 12
The potential therapeutic value and application prospect of engineered exosomes in human diseases
Liu, G., Wu, J., Chen, G., & Shang, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1051380 · Cited by 12
Dipalo, L. L., Mikkelsen, J. G., Gijsbers, R., & Carlon, M. S. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.258 · Cited by 12
“195 These factors can be harnessed and optimized toward cell-type-speci fi c delivery of gene editor RNPs.”
Briones-Márquez, L. F., Navarro‐Partida, J., Herrera-González, A., García-Bon, M. A., Martínez-Álvarez, I. A., Uribe-Rodríguez, D., González-Ortiz, L. J., & Lopez-Naranjo, E. J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20742 · Cited by 11
The Role of Extracellular Vesicles in the Treatment of Prostate Cancer
Hu, C., Chen, Q., Wu, T., Du, X., Dong, Y., Peng, Z., Xue, W., Sunkara, V., Cho, Y., & Dong, L. (2024) · Small · doi:10.1002/smll.202311071 · Cited by 11
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed
Kanbar, K., Darzi, R. E., & Jaalouk, D. E. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1434002 · Cited by 17
Qiu, J., Jiang, Y., Ye, N., Jin, G., Shi, H., & Qian, D. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05531-x · Cited by 13
“Kim et al., for instance, demonstrated that exosomes derived from SKOV3 ovarian cancer cells could undergo Exosome-liposome hybrids CRISPR/Cas9 plasmid electroporation such that they were capable of effectively inhibiting PARP-1 and thereby suppressing tumor growth [82].”
BackgroundLiu, J., Srivastava, S., Li, T., Moujane, F., Lee, J. Y., Chen, Y., Liu, H. H., Deng, S. X., & Xie, Y. (2025) · Biosensors · doi:10.3390/bios15030141 · Cited by 13
“…cancer-derived exosomes from ovarian cancer cell line SKOV3 and HEK293 as delivery vehicles for CRISPR/Cas9, to specifically target cancer cells, leveraging the cancer cell-specific tropism of these exosomes, which led to the triggering of programmed cell death in ovarian cancer cells [22].”
Tumor-derived exosomes as promising tools for cancer diagnosis and therapy
Wang, X., Liu, Y., Jiang, Y., & Li, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1596217 · Cited by 13
The Mechanism of Nano-drug Delivery
Li, S., Wang, H., & Shan, Y. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00205-5 · Cited by 12
Specific Targeting of Oncogenes Using CRISPR Technology
Oppel, F., Schürmann, M., Goon, P. K. C., Albers, A. E., & Sudhoff, H. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0571 · Cited by 11
Editing SOX Genes by CRISPR-Cas: Current Insights and Future Perspectives
Dehshahri, A., Biagioni, A., Bayat, H., Lee, E. H. C., Hashemabadi, M., Fekri, H. S., Zarrabi, A., Mohammadinejad, R., & Kumar, A. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111321 · Cited by 11
“Other less widely used methods are combining the exogen us form of the Cas9 with the selected gRNA, a formulation called ribonucleoproteins (RNPs), transferable into c lls by lipid-mediated delivery [15], xosomes-d rived ve icles [16], n o-formulati ns such as gold nanoparti-”
MethodAdvances in Intranasal Delivery of Exosomes for Central Nervous System Disorders
Arjmand, B., Mojavezi, A. R., Kamroo, A., Yazdi, R. K., Rezaei–Tavirani, M., & Vahedi, M.-S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05563-4 · Cited by 12
Smart Nanocarriers for Targeted Cancer Therapy
Martinelli, C. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200619181425 · Cited by 10
“Kim et al. demonstrated that exosomes directly injected into the tumor were able to deliver CRISPR/Cas9 targeted against PARP-1, making cells sensitive to cisplatin and inhibiting their proliferation in vivo [36].”
Exosomes: The Role in Tumor Tolerance and the Potential Strategy for Tumor Therapy
Lv, Y., Du, X., Tang, W., Yang, Q., & Gao, F. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020462 · Cited by 10
Antitumor Effect and Immunomodulatory Mechanism of “Oncolytic Extracellular Vesicles”
Feng, X., Liu, W., Jia, X., Li, F., Wang, X., Liu, X., Yu, J., Lin, X., Zhang, H., Wang, C., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02279 · Cited by 11
Synthetic and biological nanoparticles for cancer immunotherapy
Oliveira, I., Rodrigues‐Santos, P., Ferreira, L., & das Neves, R. P. (2024) · Biomaterials Science · doi:10.1039/d4bm00995a · Cited by 10
Fatima, H., Singh, D., Muhammad, H., Acharya, S., & Aziz, M. A. (2024) · 3 Biotech · doi:10.1007/s13205-024-04186-1 · Cited by 12
“Furthermore, it was discovered that SKOV3 cells were more susceptible to cisplatin when PARP-1 was inhibited through CRISPR/Cas9-mediated genome editing, which increased the cytotoxic effects (Kim et al. 2017).”
Safaei, M., Rajabi, S.-S., Tirgar, M., Namdar, N., Dalfardi, M., Mohammadifar, F., Goodarzi, A., Farmani, A. R., Ramezani, V., & Abpeikar, Z. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.03.005 · Cited by 10
“Their study aimed to inhibit the expression of the PARP-1 gene, which plays a role in the development and survival of tumors [83].”
Polymers in Engineering Extracellular Vesicle Mimetics: Current Status and Prospective
Wei, X., Liu, S., Cao, Y., Wang, Z., & Chen, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051496 · Cited by 10
“For gene loading, CRISPR-Cas9 was loaded into EVs using electroporation [102] and chemical transfection [82].”
MethodExosomes-mediated CRISPR/Cas delivery: A cutting-edge frontier in cancer gene therapy
Bhavanisha Rithiga, S., Dhar, R., & Devi, A. (2025) · Gene · doi:10.1016/j.gene.2025.149296 · Cited by 10
Lee, Y., Yoo, S., Cho, S., Kim, I., & Kim, I.-S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113885 · Cited by 9
Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progression
Azani, A., Sharafi, M., Doachi, R., Akbarzadeh, S., Lorestani, P., Olia, A. H. K., Zahed, Z., Gharedaghi, H., Ghasrsaz, H., Foroozand, H., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01771-3 · Cited by 9
“Inhibiting PARP-1 using CRISP-Cas9 resulted in SKOV3 cell (OC cell line) apoptosis and limited cancer growth [189].”
Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors
Sharma, S., Rana, R., Prakash, P., & Ganguly, N. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04715-1 · Cited by 10
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses
Fachel, F. N. S., Frâncio, L., Poletto, É., Schuh, R. S., Teixeira, H. F., Giugliani, R., Baldo, G., & Matte, Ú. D. S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114616 · Cited by 9
Zheng, Q., Wang, W., Zhou, Y., Mo, J., Chang, X., Zha, Z., & Zha, L. (2023) · Biomaterials Science · doi:10.1039/d3bm00788j · Cited by 10
Paclitaxel-loaded hybrid exosome for targeted chemotherapy of triple-negative breast cancerPreprint
Liu, J., Tang, Y.-C., Li, Y., Hu, X.-B., Huang, S. Q., Xu, W., Hao, X., Zhou, M., Wu, J., & Xiang, D. (2022) · Research Square · doi:10.21203/rs.3.rs-2144965/v1 · Cited by 9
Siraj, N., Dilfy, S. H., & Abduljaleel, R. H. (2023) · Trends in Pharmaceutical Biotechnology · doi:10.57238/tpb.2023.144271.1002 · Cited by 7
“Kim et al. achieved successful gene editing in tumor tissue by effectively utilizing tumor-derived EVs that carried the CRISPR/Cas9 system and were able to penetrate into the tumor [30].”
BackgroundHe, W., Zhu, H., Zhang, S., Shu, G., Han, L., Wang, M., Yin, G., Ni, X., & Wu, Q. (2024) · Epigenetics · doi:10.1080/15592294.2024.2357518 · Cited by 9
“…of these approaches: CRISPR-Cas9-mediated knockdown of ABCB1 reversed doxorubicin resistance in OC cells [19], BRCA1 knockout synergistically suppressed poly(ADP-ribose) polymerase (PARP)-1 expression in a mouse OC cell line (ID8), increasing sensitivity to cisplatin and PARP inhibitors [20,21].”
BackgroundHang, Y., Huang, J., Ding, M., Shen, Y., Zhou, Y., & Cai, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112820 · Cited by 8
Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy
Qi, R., Yang, J., Shen, S., Yu, Y., & Yang, Q. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01927-5 · Cited by 11
“Further experiments revealed that CRISPR/Cas9-mediated genome editing enhanced the sensitivity of ovarian cancer cells to cisplatin by inhibiting PARP-1, demonstrating a synergistic cytotoxic effect [214].”
Muhammad, S. A., Mohammed, J. S., & Rabiu, S. (2022) · Pharmaceutical Nanotechnology · doi:10.2174/2211738510666220930155253 · Cited by 8
Minicircles for a two-step blood biomarker and PET imaging early cancer detection strategy
Robinson, E. R., Gowrishankar, G., D’Souza, A. L., Kheirolomoom, A., Haywood, T., Hori, S. S., Chuang, H., Zeng, Y., Tumbale, S. K., Aalipour, A., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.026 · Cited by 8
Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment
Nawaz, A., Ariffin, N. S., & Wong, T. W. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101041 · Cited by 7
“Different types of exosomes such as cancer-derived exosomes and engineered exosomes are developed for the delivery of CRISPR-Cas9 [ 44 ,84 ].”
Pre-formation loading of extracellular vesicles with exogenous molecules using photoporation
Ramon, J., Pinheiro, C., Vandendriessche, C., Lozano−Andrés, E., Keersmaecker, H. D., Punj, D., Fraire, J. C., Geeurickx, E., Wauben, M. H. M., Vader, P., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03640-3 · Cited by 9
“For loading larger cargo molecules, genetic engineering of the producer cell line has been attempted to express the protein(s) or nucleic acid(s) of interest within the cells [31–35].”
Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications
Ren, X., Kang, C., Garcia‐Contreras, L., & Kim, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098166 · Cited by 7
“The potential other application of cancer cell exosome tropism for cancer therapy has been demonstrated using ovarian cancer cell-derived exosomes as CRISPR/Cas9 plasmid carriers to specifically deliver cargos to ovarian cancer tumors, leading to apoptosis of cancer cells [58].”
BackgroundBioengineered Exosomal Extracellular Vesicles in Cancer Therapeutics
Miles, J., André, M. D. R., Caobi, A., Ruiz, M., Nair, M., & Raymond, A. (2020) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.2020034847 · Cited by 7
Wysor, S. K., & Marcus, R. K. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c04044 · Cited by 6
Small extracellular vesicles: Multi-functional aspects in non-small cell lung carcinoma
Padinharayil, H., & George, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104341 · Cited by 7
Li, Q., Park, J.-W., Kim, J. S., Le, Q., Lee, J., & Oh, Y. (2025) · Advanced Science · doi:10.1002/advs.202415265 · Cited by 8
Progress of extracellular vesicles-based system for tumor therapy
Wang, F., Yin, L., & Hu, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.066 · Cited by 7
Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer
Yun, J., Noh, Y. R., Yoo, S., Park, S.-H., Choi, Y., An, J., & Kim, I. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040528 · Cited by 6
“The knockdown of PARP-1 via CRISPR/Cas9-loaded exosomes induced apoptosis in ovarian cancer cells and enhanced sensitivity to cisplatin, demonstrating synergistic antitumor effects [41].”
Khan, K. A., Ullah, B., Kamal, Z., Esa, M., Riaz, M., Shafique, M. S., Amanat, M. A., Rahman, A. U., Haq, A. U., Sarfraz, M., et al. (2025) · Polymer Bulletin · doi:10.1007/s00289-025-06015-8 · Cited by 6
Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
Peng, B., Jayasinghe, M. K., Le, A. H., Tran, N. M., & Le, M. T. N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.041 · Cited by 7
“–322 In in vivo applications, EVs from mesenchymal stem cells (MSCs) are a popular candidate, due to their demonstrated safety, relative ease of production, and inherent antitumor and regenerative properties.”
Setia, A., Patil, D., Randhave, N. V., Vaishali, Verma, N., Rani, K., Kale, A., Wagh, B., Kumar, V., Malik, A. K., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150582 · Cited by 9
Extracellular Vesicles in Drug Delivery: From Quality Assurance to Therapeutic Application
Zhang, K., & Fang, J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s579695 · Cited by 8
“169 Several articles have confirmed that using EVs as a platform for delivering nucleic acid molecules is more efficient than advanced lipid formulations.”
Autophagy inhibitors enhance biomolecular delivery efficiency of extracellular vesicles
Zhang, Y., Huang, M., Jiang, L., Li, T., Wang, J., Zhao, L., & Zhou, J. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.03.006 · Cited by 6
Nanoparticle-based CRISPR/Cas Delivery: An Emerging Tactic for Cancer Therapy
Dilnawaz, F., & Acharya, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666221006112615 · Cited by 7
Therapeutic Potential of Adipose Tissue Derivatives in Skin Photoaging
Liu, M., Lu, F., & Feng, J. (2023) · Regenerative Medicine · doi:10.2217/rme-2023-0098 · Cited by 5
Self-Assembled Plasmid Delivery System for PPM1D Knockout to Reverse Tumor Malignancy
Ren, X., He, X., Liu, B., Xu, C., & Cheng, S. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01009 · Cited by 6
Palkina, N. V., Zenaishvili, R. D., & Ruksha, T. G. (2024) · Vestnik dermatologii i venerologii · doi:10.25208/vdv11876 · Cited by 5
Chen, X., Yang, Z., & Li, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657956 · Cited by 5
Innovative Lipid-Based Nanobiotechnology: Diagnostics and Medicine
Seo, S. E., Kim, K. H., Singh, S., Chen, J.-S., Iijima, S., Cheng, C., Ryu, Y., Song, H. S., Li, W., & Kwon, O. S. (2026) · ACS Nano · doi:10.1021/acsnano.5c16718 · Cited by 5
Exosomes as Emerging Nanocarriers for Targeted Cancer Therapy
Du, Y., Liu, D., Liu, J., Yu, J., Hao, Z., Zhang, M., Li, J. W., & Peng, X. Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s585042 · Cited by 5
“114 Given the potent capabilities of these engineered exosomes—especially those carrying genome-editing tools or nanomaterials—evaluating their targeted efficacy and safety profile is a critical step to ensure their clinical applic - ability.”
Senevirathne, A., Hewawaduge, C., & Lee, J. H. (2021) · Veterinary Research · doi:10.1186/s13567-021-00995-x · Cited by 5
“Alternative nonviral delivery platforms, such as lipid- or polymer-based nanoparticle [7] and exosomal [8, 9] strategies, have also been attempted; however, these strategies are noninvasive, and their efficacy under in vivo conditions is very low.”
BackgroundCancer cell-derived exosomes as the delivery vehicle of paclitaxel to inhibit cancer cell growth
Kanchanapally, R., & Brown, K. (2022) · Journal of Cancer Discovery · doi:10.55976/jcd.1202217549-58 · Cited by 5
Ferronato, G. D. A., da Silveira, J. C., & Ferraz, M. D. A. M. M. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf195 · Cited by 4
Shafiq, T., Khan, N., Kausar, T., Ahmed, W., Zhang, Z., Liang, Y., & Duan, L. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s579975 · Cited by 5
“24 This method has the potential of a wide application, including HIV as well as newly developed viral infections.”
QADEER, A., Ullah, A., Khan, M. Z., Alsharif, K. F., Alzahrani, F. M., Alzahrani, K. J., & Abuderman, A. (2026) · Metabolites · doi:10.3390/metabo16030207 · Cited by 5
Li, M., Wang, Y., Zhang, H., Wang, X., He, L., & Dai, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06883-8 · Cited by 6
“…Gene PARP-1 in tumor cells Induce the apoptosis of tumor cells, enhance the chemical sensitivity and synergistic cytotoxicity of cisplatin [160] combining superparamagnetic iron oxide nanoparticles (SPIONs) with NSCLC cell-derived exosomes, which is a “dual-targeting” anti-cancer drug…”
What's in a cure: designing a broad-spectrum HIV gene therapy
Berman, R. E., Dampier, W., Nonnemacher, M. R., & Wigdahl, B. L. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000846 · Cited by 4
Exosome-Based Drug Delivery Systems
Huang, R., Zhou, J., & Chen, S. (2025) · Physiology · doi:10.5772/intechopen.1009138 · Cited by 4
Ling, L., Liang, S., Cai, M., Ge, J., Tan, H., Wang, C.-B., & Xu, B. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101646 · Cited by 4
“EVs derived from diverse sources — human blood/urine [37], stem cells [38], immune cells [39], tumor cells [40], and milk [41] — have been investigated for this purpose.”
Lu, Y., Lan, N., Zhang, Y., Nie, X., Pu, S., & Yuan, W. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5111 · Cited by 4
“were more easily internalized by tumor cells compared with EVs derived from epithelial cells (69).”
Role of Exosomes in the Treatment of Diseases
Mirzaei, H., Rahimian, N., Mirzaei, H. R., Nahand, J. S., & Hamblin, M. R. (2022) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-031-79177-2_8 · Cited by 4
Exploiting Exosomes for Cancer Diagnosis and Treatment
Kugeratski, F. G., & Kalluri, R. (2023) · Current cancer research · doi:10.1007/978-3-031-22903-9_3 · Cited by 4
The Brief Analysis of Peptide-combined Nanoparticle: Nanomedicine’s Unique Value
Wang, J., Wu, J., Li, Y., Wen, J., Cai, J., Tang, T., Hu, X.-B., & Xiang, D. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721666200210103841 · Cited by 4
Bobis‐Wozowicz, S., Kania, K., Nit, K., Błażowska, N., Kmiotek‐Wasylewska, K., Paw, M., Karnas, E., Szyposzyńska, A., Tyszka‐Czochara, M., Woźnicka, O., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.25.432823 · Cited by 4
“[35], red blood cells [36] and tumor cells [37,38] has already been demonstrated to deliver small RNAs [31] and the CRISPR/Cas9 system in vivo [32,33,36,37].”
BackgroundChen, Y., Ke, Y., Jiang, Z., & Yang, G. (2025) · Biomaterials Science · doi:10.1039/d5bm00194c · Cited by 5
Wu, R., Jin, L., Zeng, A., Xu, K., Shen, W., Ni, J., Chen, C., Zhu, Y., & Wang, J. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01556 · Cited by 3
Metadata
- Authors
- Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M.
- Affiliations
- Korea Institute of Science and Technology (KR)
- Korea University (KR)
- Corresponding author
- Jang, Mihue
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 266
- Pages
- 8-16
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2754835295
- Cited by
- 481
- References
- 39
- Citations by year
- 2026: 43 · 2025: 62 · 2024: 61 · 2023: 70 · 2022: 74 · 2021: 59 · 2020: 57 · 2019: 37 · 2018: 17 · 2017: 1
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- KIST (2E26910)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- tumor-derived exosomes, CRISPR/Cas9 delivery, ovarian cancer, apoptosis, cisplatin sensitivity, genome editing
- MeSH terms
- Poly (ADP-Ribose) Polymerase-1, Animals, Antineoplastic Agents, Cisplatin, Combined Modality Therapy, Female, Humans, Leukocytes, Mononuclear, Mice, Inbred BALB C, Mice, Nude, Neoplasms, RNA, Genetic Therapy, Cytokines, Gene Transfer Techniques, Cell Line, Tumor, Exosomes, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
